# ONESHOT: Mapping Lung Cancer Beyond Imaging

OVERVIEW

ONESHOT is an AI-powered algorithm designed to enhance lung cancer diagnosis. It integrates radiomic analysis with clinical data to improve decision-making, optimize workflows and reduce unnecessary procedures, ultimately accelerating treatment initiation.

PROJECT

Sector: Oncology, Lung cancer

R&D direction:
Radiomics and AI-driven diagnostics
Stage of development: TRL 2-3
Scientific leader: Dr. Antoni Rosell

PRODUCT

Potential indications:
Lung cancer

Mechanism of action:
AI-based multi-level analysis of CT scans and clinical data

Market Size: €3B(2024)

IP PROTECTION

Patent filed

OPPORTUNITY

License out
Spin-off generation
Co-development

NEED

Lung cancer **diagnosis is inefficient**, relying on medical imaging and invasive biopsies that can lead to delays, false positives and unnecessary interventions. Current workflows require extensive manual interpretation, **increasing workload and costs while limiting early detection capabilities**. There is a critical need for an intelligent, automated system that improves diagnostic accuracy, reduces time to treatment and optimizes healthcare resources.

SOLUTION

ONESHOT improves lung cancer diagnosis through an AI-driven, cloud-based DaaS model. By integrating advanced radiomics with clinical data, it provides multi-perspective lesion analysis at different diagnostic levels (radiological, histological and molecular). The platform operates within hospital environments via a web interface, eliminating the need for additional hardware.

KEY ADVANTATGES

- ✓ Enhanced accuracy: multi-level diagnostic models improve malignancy prediction.
- ✓ Optimized resources: reduces unnecessary tests, follow-ups and false positives.
- ✓ Simple integration: works with existing hospital IT systems via a web-based interface.